Trials / Completed
CompletedNCT04080726
Efficacy and Safety of HIP1601 Capsule
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Compare Efficacy and Safety of HIP1601 40mg and HGP1705 40mg in Patients With Erosive Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 213 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in patients with erosive gastroesphageal reflux disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HIP1601 | Oral esomeprazole |
| DRUG | HGP1705 | Oral Nexium Tab |
| DRUG | HIP1601 Placebo | Oral Placebo |
| DRUG | HGP1705 Placebo | Oral Placebo |
Timeline
- Start date
- 2018-10-25
- Primary completion
- 2019-12-03
- Completion
- 2019-12-03
- First posted
- 2019-09-06
- Last updated
- 2020-11-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04080726. Inclusion in this directory is not an endorsement.